Skip to Content
Authors Zarebczan B, Chen H
Journal Minerva Chir Volume: 65 Issue: 1 Pages: 59-69
Publish Date 2010 Feb
PubMed ID 20212418
PMC ID 2901507

Thyroid cancer is the most common malignancy of the endocrine system. There are several variants, ranging from well-differentiated cancers, such as papillary carcinomas, to poorly differentiated types, which carry a worse prognosis. Many patients with well-differentiated thyroid cancers are cured by surgical intervention alone, while others require adjuvant therapy. For those patients with more aggressive tumors, such as metastatic and anaplastic thyroid cancers, surgery rarely offers a definitive cure and alternative treatment methods such as chemotherapy do not improve survival. Due to the difficulty in treating aggressive thyroid cancers, other novel therapies are needed. In this paper, we will review current strategies for managing the various types of thyroid carcinomas. We will also address many of the studied genetic pathways and new therapeutic drug targets for treating individual thyroid malignancies.

Full Text Full text available on PubMed Central Copyright © 2017 The Board of Regents of the University of Wisconsin System